User:Mr. Ibrahem/Piflufolastat F-18

Mr. Ibrahem/Piflufolastat F-18
Clinical data
Trade names	Pylarify
Other names	18F-DCFPyL
License data	US DailyMed: Piflufolastat;
Routes of; administration	Intravenous
Drug class	Radiopharmaceutical
Legal status
Legal status	US: ℞-only;
Chemical and physical data
Formula	C18H23[18F]N4O8
Molar mass	441.4 g/mol
3D model (JSmol)	Interactive image;
	SMILES OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O;
	InChI InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1; Key:OLWVRJUNLXQDSP-MVBOSPHXSA-N;

Piflufolastat F-18, sold under the brand name Pylarify, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging.^[2] Specifically it is used to image prostate cancer that is prostate-specific membrane antigen (PSMA) positive to look for spread or recurrence.^[2] It is given by injection into a vein.^[2]

Common side effects include headache, altered taste, and tiredness.^[2] Other side effects may include allergic reactions and radiation exposure.^[2]

Piflufolastat F-18 was approved for medical use in the United States in 2021.^[2] It is not approved in either Europe or the United Kingdom as of 2022.^[1]

References[edit]

^ ^a ^b "Fluorine-18-DCFPyL". SPS - Specialist Pharmacy Service. 26 December 2019. Retrieved 29 October 2022.{{cite web}}: CS1 maint: url-status (link)
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Pylarify- piflufolastat f-18 injection". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.

[SPS2022-1] "Fluorine-18-DCFPyL". SPS - Specialist Pharmacy Service. 26 December 2019. Retrieved 29 October 2022.{{cite web}}: CS1 maint: url-status (link)

[PI2022-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Pylarify- piflufolastat f-18 injection". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.

[1]

[2]